← Leaderboards
Barbara Bedogni
Case Western Reserve University
$2,496,733
Attributed
$2,496,733
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $577.3K · FY2014–18$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$2,496,733 · 3
By mechanism
R01$1,746,765 · 1
R21$749,968 · 2
Top collaborators
No co-investigators on record.
Most similar at Case Western Reserve University
Same institution · by research overlap
- Richard L Eckert$17,347,791
- Lan Zhou$8,666,516
- Stephanie A Orellana$112,876
- Afshin Dowlati$11,024,361
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMelanomaSignal TransductionGrowthInhibitor/AntagonistCell LineNovel StrategiesPharmaceutical PreparationsSkin CancerAdverse EffectsIn VivoMalignant NeoplasmsBraf GenePathway InteractionsIn VitroLesionLapatinibMaintenanceAutomobile DrivingEmbryonic DevelopmentAppearanceHuman DiseaseCell SurvivalCombined Modality Therapy
Grant awards (10)
Targeting the developmental pathways Notch and ERBB for melanoma therapy$300,764
R01 · FY2018 · CA · contact PI
Selective inhibition of Notch1 and ERBB3 by novel neutralizing antibodies to treat melanoma$156,436
R21 · FY2018 · CA · contact PI
Targeting the developmental pathways Notch and ERBB for melanoma therapy$356,865
R01 · FY2017 · CA · contact PI
Selective inhibition of Notch1 and ERBB3 by novel neutralizing antibodies to treat melanoma$201,459
R21 · FY2017 · CA · contact PI
Targeting the developmental pathways Notch and ERBB for melanoma therapy$18,933
R01 · FY2017 · CA · contact PI
Targeting the developmental pathways Notch and ERBB for melanoma therapy$348,616
R01 · FY2016 · CA · contact PI
Targeting an MT1-MMP/MMP2 axis in melanoma by a novel MT1-MMP/MMP2 inhibitor$174,147
R21 · FY2016 · CA · contact PI
Targeting the developmental pathways Notch and ERBB for melanoma therapy$358,346
R01 · FY2015 · CA · contact PI
Targeting an MT1-MMP/MMP2 axis in melanoma by a novel MT1-MMP/MMP2 inhibitor$217,926
R21 · FY2015 · CA · contact PI
Targeting the developmental pathways Notch and ERBB for melanoma therapy$363,241
R01 · FY2014 · CA · contact PI